Biotechnology

BiomX Inc. has issued a statement addressing unusual trading activity in its stock, confirming no undisclosed material developments. The company noted recent challenges, including the discontinuation of a Phase 2b trial, cost-cutting measures, a private placement, and a reverse stock split. Despite a broader biotech sector uptick, BiomX’s shares trade below historical averages. Investor sentiment has closely followed clinical and financial news.

Genflow Biosciences appoints seasoned biotech leader Gad Berdugo as Chairman to accelerate its gene therapy pipeline for age-related diseases. Berdugo’s expertise in RNA-LNP therapeutics and U.S. market expansion is expected to drive strategic growth. Key data readouts in 2026 will be critical under his guidance, with Tamara Joseph continuing on the board for continuity.

Rigel Pharmaceuticals has granted stock options and restricted stock units to 11 non-executive employees under its Inducement Plan. This initiative, approved by the Compensation Committee, aims to attract and retain talent by aligning employee incentives with company growth. Awards vest over four years, with a one-year cliff. This equity-based compensation strategy is common in the biotech sector to foster employee commitment and shareholder value.

Monte Rosa Therapeutics is raising approximately $300 million through a public offering of common stock and pre-funded warrants. This financing aims to fuel the advancement of their novel molecular glue degrader (MGD) medicines, particularly in autoimmune diseases, oncology, and other areas. The capital infusion follows positive clinical data presentations, bolstering investor confidence and supporting the company’s proprietary QuEEN™ discovery engine.

Molecular Partners will present pipeline updates and its 2025 outlook at the J.P. Morgan Healthcare Conference. CEO Patrick Amstutz will discuss advancements in their novel DARPin drug technology, focusing on oncology. The presentation, webcast live, is expected to detail clinical progress, strategic direction, and financial projections for the coming year, offering insights into the company’s innovative therapeutic approach and market potential.

Onco‑Innovations announced it has hired a U.S. investment bank to advise on a possible Nasdaq cross‑listing and assess a concurrent equity financing. The advisory will evaluate listing requirements, regulatory and governance issues, and capital‑raising strategies. While the engagement signals interest in U.S. market access and additional capital, the company cautions that neither a listing nor financing is guaranteed and details remain under discussion.

Vor Bio (Nasdaq: VOR) announced the pricing of a public offering of 10,000,000 common shares at $10.00 per share, expecting $100 million in gross proceeds. The offering is anticipated to close around November 12, 2025, subject to closing conditions. Underwriters, including J.P. Morgan and Jefferies, have a 30-day option to purchase up to 1,500,000 additional shares. The shares are being sold under an existing shelf registration. A final prospectus supplement will be filed with the SEC and available via the underwriters.

Evommune, Inc. announced the pricing of its IPO of 9,375,000 shares at $16.00 per share, expected to begin trading on the NYSE (EVMN) on November 6, 2025. The offering is anticipated to close on November 7, 2025, and includes an underwriter option for additional shares. Gross proceeds are projected at $150 million. Morgan Stanley, Leerink Partners, Evercore ISI, and Cantor are joint book-runners. Evommune will use the funds to advance its pipeline of therapies targeting chronic inflammatory diseases.